In 2024, administration of the four FDA-approved RSV vaccinations was low, ranging from 0.27% to 0.58%, according to a poster ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

In recent years, the familiar symptoms of the flu might kick us into reaching for at-home testing kits. But on the eve of the ...

The United Kingdom’s Health Security Agency (HSA) yesterday published it first annual report on infectious disease trends, which weaves together data from 2023 through early 2025 and reveals that ...

Despite ongoing research efforts, an effective RSV vaccine has yet to be approved for widespread use. Use of two separate pattern recognition receptor (PRR) agonists as adjuvants in vaccine ...

Vaccine effectiveness against documented RSV infections was 78.1% (95% CI, 72.6-83.5), with incidence rates of infections lower in the vaccinated group than in the unvaccinated group (1.7 vs 7.3 ...

Karen Y. Capusan, DNP, CPNP-PC, explored RSV’s shifting epidemiology, seasonal trends, and new vaccines’ role in reducing hospitalizations at the 2025 NAPNAP National Conference. At the 2025 NAPNAP ...

In recent years our understanding of infectious-disease epidemiology and control has been greatly increased through mathematical modelling. Insights from this increasingly-important, exciting field ...

More Alberta seniors are now eligible for a provincially funded RSV vaccine. The provincial government announced in October it would provide the RSV shot, Abrysvo, for free to seniors 60 and up ...